Prexasertib can also be combined with PD-L1 antibody LY3300054 (NCT03495323) to activate the cytotoxic T-cell in Cyclin E1 (CCNE1)-amplified high-grade serous ovarian-cancer (HGSOC) patients [344]. The gene discussed is CCNE1; the disease is ovarian serous adenocarcinoma.